Management nicht-motorischer Störungen bei Morbus Parkinson – Schritt für Schritt

Die zielgerichtete Diagnostik und der Einsatz von effektiven Therapiemethoden bei nicht-motorischen Störungen (NMS) ist ein sehr wichtiger Baustein in der Behandlung von Patient*innen mit Morbus Parkinson. Der wichtigste Schritt auf dem Weg zu einer effektiven Therapie ist, NMS zu erkennen und richtig einzuordnen. Der Artikel führt in die rationale Diagnostik ein und bietet einen Überblick über die zur Verfügung stehenden Therapiemethoden.

Schlüsselwörter

idiopathisches Parkinson-Syndrom (IPS) - nicht-motorische Störungen - autonome Störung - Dysautonomie - sensorische Störung - neuro-psychiatrische Störung

Publication History

Article published online:
03 March 2023

• Literatur

• 1 Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368-76
• 2 Moustafa AA, Chakravarthy S, Phillips JR. et al. Motor symptoms in Parkinson’s disease: A unified framework. Neurosci Biobehav Rev 2016; 68: 727-740
• 3 Banks SJ, Bayram E, Shan G. et al. Non-motor predictors of freezing of gait in Parkinson‘s disease. Gait Posture 2019; 68: 311-316
• 4 Lopez AM, Weintraub D, Claassen DO. Impulse control disorders and related complications of Parkinson's disease therapy. Semin Neurol 2017; 37: 186-192
• 5 Voon V. et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol 2011; 11: 117
• 6 Schneider C, Storch A. Skalen und Scores zur Erfassung nicht motorischer Symptome beim Morbus Parkinson. Nervenheilkunde 2012; 31: 879-883
• 7 Kalia LV, Lang AE. Parkinson's disease. Lancet 2015; 386: 896-912
• 8 Barone P, Erro R, Picillo M. Quality of Life and Nonmotor Symptoms in Parkinson‘s Disease. Int Rev Neurobiol 2017; 133: 499-516
• 9 Pfeiffer RF. Non-motor symptoms in Parkinson‘s disease. Parkinsonism Relat Disord 2016; 22 (Suppl. 01) S119-S122
• 10 Engels G, Douw L, Kerst Y. et al. Non-motor symptoms in Parkinson's disease: An explorative network study. Parkinsonism Relat Disord 2019; 66: 237-240
• 11 Braak H. et al. Staging of brain pathology related to sporadic Parkinson‘s disease. Neurobiol Aging 2003; 24: 197-211
• 12 Sauerbier A, Jenner P, Todorova A. et al. Non motor subtypes and Parkinson‘s disease. Parkinsonism Relat Disord 2016; 22 (Suppl. 01) S41-46
• 13 Marras C, Chaudhuri KR. Nonmotor features of Parkinson‘s disease subtypes. Mov Disord 2016; 31: 1095-1102
• 14 Titova N, Chaudhuri RK. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust 2018; 208: 404-409
• 15 Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nature Reviews Neuroscience 2017; 18
• 16 Deuschl G, Oertel W, Reichmann H. DGN-Leitlinie Parkinson-Syndrom, idiopathisch. Registernummer 030–010. Klassifikation S3. Stand: 01.01.2016–01–01 (in Überarbeitung), gültig bis 31.12.20.
• 17 Videnovic A, Klerman EB, Zee PC. Light Therapy Promoting Dopamine Release by Stimulating Retina in Parkinson Disease-Reply. JAMA Neurol 2017; 74: 1268-1269
• 18 Warnecke T, Schäfer KH, Claus I. et al. Gastrointestinal involvement in Parkinson‘s disease: pathophysiology, diagnosis, and management. NPJ Parkinsons Dis 2022; 8: 31
• 19 Tan AH, Lim SY, Chong KK. et al. Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. Neurology 2021; 96: e772-e782
• 20 Chaudhuri KR, Healy DG, Schapira AH. National Institute for Clinical Excellence. Non-motor symptoms of Parkinson‘s disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245
• 21 Chaudhuri KR, Martinez-Martin P, Schrag A. International Parkinson and Movement Disorder Society. et al. MDS-NMS. International Parkinson and Movement Disorder Society – Non-Motor Rating Scale. 2019 Accessed January 18, 2023 at: https://www.movementdisorders.org/MDS-Files1/PDFs/Rating-Scales/MDS-NMS_FINAL.pdf
• 22 Chaudhuri KR, Martinez-Martin P, Schapira AHV. et al. International Multicenter Pilot Study of the First Comprehensive Self-Completed Nonmotor Symptoms Questionnaire for Parkinson’s Disease: The NMSQuest Study. Movement Disorders 2006; 21: 916-923
• 23 Savitt J, Aouchiche R. Management of visual dysfunction in patients with Parkinson‘s disease. J Parkinsons Dis 2020; 10: S49-S56
• 24 Armstrong RA. Oculo-visual dysfunction in Parkinson‘s disease. J Parkinson Dis 2015; 5: 715-726
• 25 Park JS, Park D, Ko PW. et al. Serum methylmalonic acid correlates with neuropathic pain in idiopathic Parkinson‘s disease. Neurol Sci 2017; 38: 1799-1804
• 26 Qiu F, Wu Y, Cao H. et al. Changes of peripheral nerve function and vitamin B12 level in people with Parkinson‘s disease. Front Neurol 2020; 11: 549159
• 27 Goldstein DS. Cardiac sympathetic denervation in Parkinson didease. Ann Intern Med 2000; 113: 338-447
• 28 Dafsari HS, Petry-Schmelzer JN, Ray-Chaudhuri K. EUROPAR; IPMDS Non Motor PD Study Group. et al. Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. Brain Stimul 2018; 11: 904-912
• 29 Csoti I, Fornadi F. Schwerpunkt. Medikamentöse Interaktionen in der Parkinson-Therapie. NeuroGer 2008; 5: 160-168
• 30 Barone P, Antonini A, Colosimo C. PRIAMO study group. et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson‘s disease. Mov Disord 2009; 24: 1641-1649
• 31 https://www.medtronic.com/de-de/fachkreise/therapien-prozeduren/neurologie-schmerztherapie/tiefe-hirnstimulation.html
• 32 Klebe S, Coenen V. Hirnstimulation bei neurologischen und psychiatrischen Erkrankungen. Nervenarzt 2021; 92: 1042-1051